Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...

Unlike the Get Better campaign — which was built throughout last year — Seeking launched with a full body of creative work, ...

Eli Lilly has spent the last several years reintroducing itself to the public via a series of corporate campaigns. | Eli Lilly has spent the last several years reintroducing itself to the public via a ...

Currently trailing Eli Lilly and Structure Therapeutics in the oral weight loss space, Novo Nordisk strikes a deal with ...

Branded drug manufacturers, including Eli Lilly and Company (Eli Lilly), have been pursuing various legal actions against compounding pharmacies ...

Sangamo Therapeutics Inc (SGMO) reports significant milestones and strategic initiatives, despite financial challenges, in ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Don’t miss this list of 3 ...

Eli Lilly and Company’s LLY shares have lost 17 ... Mounjaro is the market leader in new prescription within type II diabetes incretin analogs. In the first quarter, Zepbound held the leading ...

The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.